A clinical study revealed that neurotransmitters could trigger the postsynaptic signalling pathways bound to cognition which supported the hypothesis that H3R is a drug target for cognitive disorders3,6,11,12, especially for Alzheimer Disease (AD), schizophrenia and epilepsy.13–16. The gene discussed is HRH3; the disease is Alzheimer disease.